What is Satellos?
Satellos is a biotechnology firm focused on advancing treatments for Duchenne muscular dystrophy and other muscle-debilitating diseases. Leveraging its proprietary MyoReGenX platform, the company aims to restore the body's natural muscle regeneration capabilities by targeting the AAK1 protein, which is critical for muscle stem cell function. Their approach seeks to address the underlying mechanisms of muscle repair disrupted by conditions like the absence of dystrophin, offering a new avenue for therapeutic intervention.
How much funding has Satellos raised?
Satellos has raised a total of $41M across 2 funding rounds:
Corporate Investment
$1M
Other Financing Round
$40M
Corporate Investment (2021): $1M with participation from Parent Project Muscular Dystrophy
Other Financing Round (2024): $40M led by Haywood, Bloom Burton, LeedCo Financial Group, and Canaccord Genuity
Key Investors in Satellos
Parent Project Muscular Dystrophy
Parent Project Muscular Dystrophy is an organization dedicated to accelerating research and finding a cure for Duchenne muscular dystrophy.
Haywood
Haywood is an investment bank providing research and advisory services, likely focusing on emerging companies in sectors like biotechnology.
Bloom Burton
Bloom Burton & Co. is a specialized investment firm concentrating on the healthcare sector, offering capital raising and strategic advisory services.
What's next for Satellos?
The recent major enterprise-level funding positions Satellos for accelerated development and potential commercialization of its small molecule therapeutics. This strategic investment will likely fuel further research and clinical trials, aiming to validate the efficacy of their platform in improving outcomes for patients with severe muscle diseases. The company's focus on reactivating natural repair processes suggests a long-term strategy to address unmet needs in regenerative medicine.
See full Satellos company page
